Clinical Trials Logo

Hepatitis B clinical trials

View clinical trials related to Hepatitis B.

Filter by:

NCT ID: NCT03957629 Recruiting - Hepatitis B Clinical Trials

Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis

Start date: November 6, 2019
Phase: N/A
Study type: Interventional

Compared to TDF, peginterferon alfa 2a may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. We design this study to compare the effectiveness and safety between the combination therapy of TDF and peg-IFN with TDF alone in NAs experienced patients with HBV related liver fibrosis. Especially the improvement of liver fibrosis and the occurrence of long-term end-stage liver disease such as cirrhosis, liver cancer, etc.

NCT ID: NCT03934736 Active, not recruiting - Clinical trials for End Stage Renal Disease on Dialysis (Diagnosis)

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Start date: April 29, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, single arm study design to evaluate HEPLISAV-B® in adults with ESRD who are initiating or undergoing hemodialysis.

NCT ID: NCT03933384 Recruiting - Hepatitis B Clinical Trials

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

Start date: August 19, 2019
Phase: Phase 4
Study type: Interventional

To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.

NCT ID: NCT03932851 Recruiting - Pregnancy Clinical Trials

Clinical Study on the Effect of IVF-ET on Mother-to-child Transmission of Hepatitis B Virus

Start date: August 1, 2018
Phase:
Study type: Observational

This study is intended to retrospectively collect HBV-infected pregnant women and non-HBV-infected pregnant women who have been born in IVF in the investigators' hospital, collect pregnant women's data during pregnancy, newborn birth data, and hepatitis B virus in July after birth of newborns born to HBV-infected pregnant women. Infection, explore the impact of HBV infection on IVF outcomes and whether IVF operations increase the risk of mother-to-child transmission of HBV.

NCT ID: NCT03932513 Terminated - Hepatitis B Clinical Trials

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

Start date: April 11, 2019
Phase: Phase 2
Study type: Interventional

A single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose per day and three times per week on immune response and viral markers in virally suppressed patients with chronic hepatitis B infection

NCT ID: NCT03931239 Completed - Hepatitis B Clinical Trials

The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate safety and tolerability of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine Adsorbed in Vietnamese infants aged 6-12 weeks. This is an open label, single group, bridging study.

NCT ID: NCT03920618 Recruiting - Hepatitis B Clinical Trials

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

HBV
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.

NCT ID: NCT03920605 Recruiting - Hepatitis B Clinical Trials

Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis

HBV
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. We design this study to investigate treatment of peginterferon alfa 2a/2b in anti-virus treatment experienced patients with HBV related liver fibrosis.

NCT ID: NCT03919578 Completed - Immunogenicity Clinical Trials

Protectivity and Safety Following Recombinant Hepatitis B Vaccine

Start date: September 11, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population

NCT ID: NCT03919565 Recruiting - Hepatitis B Clinical Trials

Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis

HBV
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. We design this study to investigate treatment of peginterferon alfa 2a/2b in anti-virus treatment naive patients with HBV related liver fibrosis.